quality and affordable protein therapeutics
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 5 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.
Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.
At present, Henlius has 6 products launched in China, 4 approved for marketing in overseas markets, and 5 marketing applications under review in China, the U.S. and the EU, respectively. Meanwhile, Henlius has conducted over 30 clinical studies for 19 products globally. HANLIKANG (rituximab injection), the first product of Henlius, has been approved by the National Medical Products Administration (NMPA) as China's first biosimilar. The second product HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe) is a Chinese mAb biosimilar approved in the U.S. the EU and China, bringing more treatment options to patients with HER2 positive breast and gastric cancer worldwide. The company’s first self-developed innovative monoclonal antibody HANSIZHUANG (serplulimab, trade name: Hetronifly® in the EU) is the world’s first anti-PD-1 mAb for the first-line treatment of SCLC.
Products
Marketing applications under review
Candidates
Clinical Studies
